Arrestins in the Cardiovascular System - Progress in Molecular Biology and Translational Science - page 322

74. Mundell SJ, Benovic JL. Selective regulation of endogenous G protein-coupled recep-
tors by arrestins in HEK293 cells. J Biol Chem . 2000;275:12900 - 12908.
75. Calegari VC, Bezerra RM, Torsoni MA, et al. Suppressor of cytokine signaling 3 is
induced by angiotensin II in heart and isolated cardiomyocytes, and participates in
desensitization. Endocrinology . 2003;144:4586 - 4596.
76. Hein L, Meinel L, Pratt RE, Dzau VJ, Kobilka BK. Intracellular trafficking of angio-
tensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and
ligand. Mol Endocrinol . 1997;11:1266 - 1277.
77. Thomas WG, Thekkumkara TJ, Baker KM. Cardiac effects of AII. AT1A receptor sig-
naling, desensitization, and internalization. Adv Exp Med Biol . 1996;396:59 - 69.
78. Richard DE, Laporte SA, Bernier SG, Leduc R, Guillemette G. Desensitization of AT1
receptor-mediated cellular responses requires long term receptor down-regulation in
bovine adrenal glomerulosa cells. Endocrinology . 1997;138:3828 - 3835.
79. Zidar DA, Violin JD, Whalen EJ, Lefkowitz RJ. Selective engagement of G protein
coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl
Acad Sci USA . 2009;106:9649- 9654.
80. Boerrigter G, LarkMW, Whalen EJ, Soergel DG, Violin JD, Burnett Jr JC. Cardiorenal
actions of TRV120027, a novel b -arrestin-biased ligand at the angiotensin II type
I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute
heart failure. Circ Heart Fail . 2011;4:770 - 778.
81. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union
of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev . 2000;52:
415 - 472.
82. MacKenzie A. Endothelium-derived vasoactive agents, AT1 receptors and inflamma-
tion. Pharmacol Ther . 2011;131:187 - 203.
83. Weber KT. Aldosterone in congestive heart failure. N Engl J Med . 2001;345:

1689- 1697.
84. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol . 2005;186:1 - 20.
85. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) .

2007;113:267- 278.
86. Richards AM. Mineralocorticoid receptor antagonists for heart failure. Expert Opin
Pharmacother . 2011;12:2801 - 2815.
87. Ganguly A, Davis JS. Role of calcium and other mediators in aldosterone secretion
from the adrenal glomerulosa cells. Pharmacol Rev . 1994;46:417 - 447.
88. Harvey AN, Nguyen K, Lymperopoulos A. GRK2 and beta-arrestins in cardiovascular
disease: established and emerging possibilities for therapeutic targeting. Curr Mol
Pharmacol 2012. 2011 Jun 15 [Epub ahead of print].
89. Turu G, Szidonya L, G´borik Z, et al. Differential beta-arrestin binding of AT1 and
AT2 angiotensin receptors. FEBS Lett . 2006;580:41 - 45.
90. Ivey ME, Osman N, Little PJ. Endothelin-1 signalling in vascular smooth muscle: path-
ways controlling cellular functions associated with atherosclerosis. Atherosclerosis .
2008;199:237- 247.
91. Vignon-Zellweger N, Heiden S, Miyauchi T, Emoto N. Endothelin and endothelin
receptors in the renal and cardiovascular systems. Life Sci . 2012;91:490 - 500.
92. Stockand JD. Vasopressin regulation of

renal sodium excretion. Kidney Int .

2010;78:849 - 856.
93. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS. Differential affinities of visual
arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two
major classes of receptors. J Biol Chem . 2000;275:17201 - 17210.
94. Lymperopoulos A, Bathgate A. Pharmacogenomics of the heptahelical receptor regu-
lators G-protein-coupled receptor kinases and arrestins: the known and the unknown.
Pharmacogenomics . 2012;13:323 - 341.